David Weidman, MD - Therapeutic Advances in the Early Treatment of Alzheimer’s Disease: Expert Insights on Novel Biomarkers and Emerging Disease-Modifying Therapies episode artwork

EPISODE · Jul 11, 2022 · 36 MIN

David Weidman, MD - Therapeutic Advances in the Early Treatment of Alzheimer’s Disease: Expert Insights on Novel Biomarkers and Emerging Disease-Modifying Therapies

from PeerView Clinical Pharmacology CME/CNE/CPE Video · host PVI, PeerView Institute for Medical Education

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer’s disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Episode metadata supplied by the publisher feed · Published Jul 11, 2022

Embed this episode

Ready to play

David Weidman, MD - Therapeutic Advances in the Early Treatment of Alzheimer’s Disease: Expert Insights on Novel Biomarkers and Emerging Disease-Modifying Therapies

0:00 36:55

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of PeerView Clinical Pharmacology CME/CNE/CPE Video?

This episode is 36 minutes long.

When was this PeerView Clinical Pharmacology CME/CNE/CPE Video episode published?

This episode was published on July 11, 2022.

Can I download this PeerView Clinical Pharmacology CME/CNE/CPE Video episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!